PR
PRCT.US Procept Biorobotics Corp
- Market cap
- USD 1.35B
- P/E
- -
- P/B
- 4.17x
- ROE
- -34.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRCT.US undervalued?
Graham numberThe Graham number of Procept Biorobotics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Procept Biorobotics Corp fundamental analysis
No fundamental analysis for Procept Biorobotics Corp yet.
Procept Biorobotics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males s…
Full company profileProcept Biorobotics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Procept Biorobotics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6.17M | 7.72M | 34.5M | 75.0M | 136M | 224M | 308M | 368M |
| Gross Profit | -1.89M | -1.26M | 15.9M | 37.1M | 71.0M | 137M | 196M | 242M |
| Operating Income | -43.6M | -47.8M | -54.2M | -80.7M | -109M | -96.6M | -104M | -116M |
| EBITDA | -39.8M | -44.9M | -50.7M | -79.1M | -98.1M | -82.0M | -85.4M | -102M |
| Net Income | -42.0M | -53.0M | -59.9M | -87.2M | -106M | -91.4M | -95.6M | -113M |
| EPS | -1.25 | -1.51 | -1.37 | -1.96 | -2.24 | -1.75 | -1.72 | -1.98 |
| Balance Sheet | ||||||||
| Total Assets | 62.0M | 126M | 337M | 309M | 405M | 534M | 508M | 474M |
| Total Liabilities | 32.8M | 65.0M | 69.9M | 112M | 124M | 132M | 142M | 145M |
| Shareholders' Equity | 29.2M | 61.0M | 267M | 197M | 281M | 402M | 366M | 329M |
| Cash & Short-term Investments | 42.0M | 100M | 304M | 223M | 257M | 334M | 287M | 218M |
| Total Debt | 23.2M | 54.8M | 54.1M | 77.3M | 79.2M | 80.3M | 78.5M | 77.0M |
| Cash Flow | ||||||||
| Operating Cash Flow | -43.8M | -48.3M | -57.3M | -80.4M | -108M | -99.2M | -49.0M | -139M |
| Capital Expenditure | 7.61M | 233K | 592K | 2.65M | 25.2M | 4.41M | 9.36M | 12.6M |
| Free Cash Flow | -51.4M | -48.6M | -57.9M | -83.0M | -133M | -104M | -58.3M | -152M |
| Ratios | ||||||||
| ROE | -143.6% | -87.0% | -22.4% | -44.2% | -37.7% | -22.7% | -26.1% | -34.5% |
| ROA | -67.7% | -42.1% | -17.8% | -28.2% | -26.2% | -17.1% | -18.8% | -23.9% |
| Net Profit Margin | -680.4% | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% | -30.8% |
| Debt to Equity | 0.79x | 0.90x | 0.20x | 0.39x | 0.28x | 0.20x | 0.21x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Procept Biorobotics Corp dividends
Procept Biorobotics Corp has not paid dividends in the last 7 fiscal years.
Who owns Procept Biorobotics Corp
- Insiders 3.46%
- Institutions 96.54%
- Public & others 0.00%
- Shares outstanding 57.5M
- Free float 56.0M
Top funds holding PRCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.71M | 2.97% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.41M | 2.45% | 0.00% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 1.31M | 2.27% | -0.57% | Sep 2026 |
| Vanguard Small Cap Index | 1.23M | 2.13% | -1.42% | Sep 2026 |
| Janus Henderson Venture D | 1.07M | 1.86% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 696K | 1.21% | 0.00% | Sep 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 691K | 1.20% | -0.07% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 682K | 1.19% | -4.27% | Sep 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 666K | 1.16% | +9.00% | Jan 2026 |
| BNP Paribas US Small Cap ClassicC | 638K | 1.11% | -0.76% | Sep 2026 |
| Fidelity Small Cap Index | 622K | 1.08% | +1.40% | Aug 2026 |
| T. Rowe Price New Horizons | 615K | 1.07% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 531K | 0.92% | -0.38% | Oct 2026 |
| Global X Robotics & Artfcl Intllgnc ETF | 477K | 0.83% | -0.10% | Oct 2026 |
| Champlain Small Company Adv | 401K | 0.70% | -22.44% | Jun 2026 |
| Federated Hermes MDT Small Cap Core IS | 397K | 0.69% | -34.69% | Sep 2026 |
| AXAWF Robotech G Cap USD | 394K | 0.68% | -0.56% | Sep 2026 |
| Edinburgh Worldwide Ord | 379K | 0.66% | +75.83% | Aug 2026 |
| C WorldWide Healthcare Select 1A | 375K | 0.65% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 326K | 0.57% | +1.02% | Sep 2026 |
Top institutions holding PRCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.87M | 8.46% | +11.64% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 3.27M | 5.68% | -0.25% | Jun 2026 |
| BNP Paribas Investment Partners SA | 2.82M | 4.91% | -8.59% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.53M | 4.39% | +4.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.46M | 4.28% | +2.57% | Jun 2026 |
| Chicago Capital LLC | 2.07M | 3.60% | -4.04% | Jun 2026 |
| State Street Corp | 1.62M | 2.81% | +5.74% | Jun 2026 |
| Geode Capital Management, LLC | 1.48M | 2.58% | +8.85% | Jun 2026 |
| FMR Inc | 1.44M | 2.51% | -1.16% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.33M | 2.32% | +119.89% | Jun 2026 |
| Wellington Management Company LLP | 1.27M | 2.21% | +47.86% | Jun 2026 |
| Federated Hermes Inc | 1.25M | 2.18% | +618.56% | Jun 2026 |
| Baillie Gifford & Co Limited. | 1.20M | 2.09% | +32.03% | Sep 2026 |
| Jupiter Topco LLC | 1.10M | 1.92% | 0.00% | Jun 2026 |
| Frontier Capital Management CO Inc | 1.09M | 1.90% | +78.98% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.00M | 1.74% | +526.88% | Jun 2026 |
| Champlain Investment Partners, LLC | 981K | 1.71% | -13.64% | Jun 2026 |
| Fiera Capital Corporation | 775K | 1.35% | -19.95% | Jun 2026 |
| LMR Partners LLP | 722K | 1.25% | 0.00% | Jun 2026 |
| William Blair Investment Management, LLC | 709K | 1.23% | +67.21% | Jun 2026 |
Procept Biorobotics Corp company profile
- Company name
- Procept Biorobotics Corp
- Ticker
- PRCT.US
- Exchange
- USA Stocks
- Listed since
- Sep 15, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 888
- Fiscal year end
- December
- Address
- 150 Baytech Drive, San Jose, CA, United States, 95134
- Phone
- 650 232 7200
- Website
- procept-biorobotics.com
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Procept Biorobotics Corp management
10- Mr. Larry L. WoodPresident, CEO & Director · born 1966
- Mr. Kevin WatersExecutive VP & CFO · born 1977
- Ms. Alaleh NouriEVP, Chief Legal Officer & Corporate Secretary · born 1979
- Mr. Christofer ChristoforouExecutive Vice President of Operations · born 1970
- Mr. Barry TemplinExecutive VP & CTO
- Mr. Matthew James Bacso C.F.A.Vice President of Investor Relations
- Ms. Pooja Sharma RaoExecutive VP and Chief Strategy & Marketing Officer
- Ms. Stacey L. PorterExecutive VP & Chief People Officer · born 1975
- Mr. Bijesh ChandranExecutive Vice President of Regulatory Affairs & Quality Assurance
- Mr. Stephen J. McGillSenior VP & GM of International · born 1962